الفهرس 
Clinical significanceOnly 14 pages are availabe for public view
 |  | from | 183 |  |  |
| | | from | 183 | | |
Abstract
After allogeneic stimulation, some uremic patients produce cytotoxic alloreactive antibodies (allo-Ab), as determined by the microcytotoxicity assay, and some do not. We believe that the mechanisms by which some patients produce lymphocytotoxins, while others do not, should give scientists an excellent model to study tolerance and memory cell function. Investigating the immunological basis of allosensitization is important as it can help us to: 1) develop the necessary strategy to abrogate the continuous production of allo-Ab, thereby increasing the chance of sensitized patients for future transplantation; 2) understand memory alloreactive B cell function in humans; 3) understand and treat chronic allograft rejection because continuous B cell alloreactivity plays a significant role in chronic rejection; and 4) understand the complex interaction between B and T lymphocytes. The exact mechanism(s) byswhich some uremic patients maintain the production of allo-Ab in.their sera hi the absence of continuous stimulation is not known.